Achieved CR | Did not achieve CR | |||
---|---|---|---|---|
Characteristic | Glasdegib + LDAC N = 15 | LDAC alone N = 1 | Glasdegib + LDAC N = 63 | LDAC alone N = 37 |
Age (years), n (%) | ||||
45–64 | 0 | 0 | 1 (1.6) | 1 (2.7) |
≥ 65 | 15 (100) | 1 (100) | 62 (98.4) | 36 (97.3) |
Median (range) | 74 (65–87) | 78 (78–78) | 77 (64–92) | 76 (58–83) |
Sex, n (%) | ||||
Female | 5 (33.3) | 1 (100) | 14 (22.2) | 14 (37.8) |
Male | 10 (66.7) | 0 | 49 (77.8) | 23 (62.2) |
ECOG PS, n (%) | ||||
0 | 0 | 1 (100) | 10 (15.9) | 2 (5.4) |
1 | 5 (33.3) | 0 | 21 (33.3) | 17 (45.9) |
2 | 10 (66.7) | 0 | 31 (49.2) | 18 (48.6) |
Not reported | 0 | 0 | 1 (1.6) | 0 |
Cytogenetic risk, n (%) | ||||
Good/intermediate risk | 12 (80.0) | 0 | 41 (65.1) | 22 (59.5) |
Poor risk | 3 (20.0) | 1 (100) | 22 (34.9) | 15 (40.5) |
ELN risk stratification, n (%) | ||||
Favorable | 1 (6.7) | 0 | 4 (6.3) | 3 (8.1) |
Intermediate I | 8 (53.3) | 0 | 19 (30.2) | 11 (29.7) |
Intermediate II | 3 (20.0) | 0 | 18 (28.6) | 8 (21.6) |
Adverse | 3 (20.0) | 1 (100) | 22 (34.9) | 15 (40.5) |
Disease history, n (%) | ||||
De novo | 7 (46.7) | 1 (100) | 31 (49.2) | 17 (45.9) |
Secondary AML | 8 (53.3) | 0 | 32 (50.8) | 20 (54.1) |
Mutations, n (%)* | ||||
FLT3† | 0 | 0 | 5 (7.9) | 0 |
IDH1 or IDH2 | 4 (26.7) | 0 | 15 (23.8) | 6 (16.2) |
NPM1 | 1 (6.7) | 0 | 4 (6.3) | 1 (2.7) |
Unknown | 4 (26.7) | 0 | 16 (25.4) | 13 (35.1) |